Drug Discovery World

APRIL 8, 2024

The American Association of Cancer Research (AACR) Annual Meeting launched on Sunday 7 April in San Diego with an Opening Plenary Session showcasing cutting-edge technological advances opening new frontiers in cancer science.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Scienmag

NOVEMBER 16, 2020

Singapore scientists uncover potential role of long non-coding RNAs in pancreatic cancer Credit: From Figure 4 in Liu, S., Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation. Harmston, N., Glaser, T.L. Genome Med 12, 89 (2020).

In-Vivo 53

In-Vivo RNA DNA Genome 53

Drug Discovery World

NOVEMBER 15, 2022

Discover how in vitro assays can be used to model in vivo neurodegeneration. Discover how in vitro assays can be used to model in vivo neurodegeneration. Brought to you by DDW and Malvern Panalytical, the webinar is presented by Dr Elise Malavasi, Principal Scientist at Concept Life Sciences. Watch the webinar now.

In-Vitro 52

In-Vitro Drugs In-Vivo Life Science 52

Drug Discovery World

MAY 29, 2023

As a provider of AAV viral vectors, VectorBuilder has played a crucial role in freeing up our time to focus more on research by providing large quantities of high-quality viral vector for in vivo applications,” said Martin Madill, Senior Scientist at Purespring Therapeutics.

Gene Therapy 52

Gene Therapy In-Vivo Gene Sales 52

Scienmag

FEBRUARY 22, 2021

Using innovative in vivo imaging approaches, scientists […]. Some make use of the immune system to act and belong to a class of treatment called “immunotherapies.” ” But how do these antibodies function within the tumor? And how can we hope to improve their efficacy?

In-Vivo 41

In-Vivo Antibody Scientist Allergies 41

Drug Discovery World

JUNE 19, 2023

Anoat will use the funds to conduct additional in vivo and in vitro pharmacology assessments and select a lead candidate. AdBio Partners’ mission is to support founding scientists in the development of new therapeutic approaches,” said Alain Huriez, Managing Partner of AdBio Partners.

Development 52

Development Life Science In-Vivo In-Vitro 52

Drug Discovery World

APRIL 5, 2023

We will be collaborating closely with the consortium’s network of scientists to help fuel the world’s discovery engine in the fight against cancer.” Members contribute their expertise in high throughput screening, structural biology, medicinal chemistry, compound profiling, cancer cell biology, and in vivo and in vitro models for oncology.

Drugs 52

Drugs In-Vivo In-Vitro Engineer 52

Drug Discovery World

MARCH 4, 2024

By effectively running bioassays and analysing results, drug developers can efficiently optimise lead compounds, predict in vivo efficacy, and gain insights into the mechanism of action. RA: Does assay annotation remove some of the burden scientists face when performing/ analysing assays?

Drugs 59

Drugs Bioassay Scientist In-Vivo 59

Drug Discovery World

SEPTEMBER 21, 2022

Scientists have discovered a type of breast cancer cell that is highly efficient in invading and colonising distant organs and slow their growth once there to evade therapies. Scientists also found in animal models that these unique cells slow and stop their own growth, keeping them in a dormant state in distant organs such as the lungs.

Regulation 52

Regulation Protein In-Vivo Scientist 52

Drug Discovery World

MARCH 15, 2024

Disease-modifying therapy for Parkinson’s The Nature Communications paper, published in November 2023 by scientists at Cambridge University, Harvard University and Mission Therapeutics, provided key experimental evidence to support the thesis that MTX325 can modify the course of Parkinson’s by targeting USP30.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vivo Trials 52

Drug Discovery World

JANUARY 27, 2023

This comes just as Myosana has appointed its new CEO, Dr Matthew Lumley, a physician scientist who has spent nearly two decades in academic medicine and drug development. As proof of principle for the platform, success in treating Duchenne would open up opportunities for Myosana to target a large range of neuromuscular and cardiac diseases.”

Gene Therapy 52

Gene Therapy Gene In-Vivo Development 52

Drug Discovery World

MAY 9, 2023

The recent passage of the FDA Modernization Act, which removed the requirement for animal testing when suitable alternatives are available, has highlighted the inadequacy of animal models most often used for in vivo research. Cancer is far more complex than the sum of its parts. Mice have long been heroes of preclinical cancer research.

Development 52

Development Drugs In-Vivo Clinical Trials 52

Scienmag

OCTOBER 23, 2020

Oncotarget recently published a novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo which reported that here, the authors describe four novel formats for the L19-IL2 fusion Credit: Correspondence to – Dario Neri – dario.neri@pharma.ethz.ch

Recombinant Antibody 53

Recombinant Antibody Protein Antibody In-Vivo 53

pharmaphorum

AUGUST 5, 2021

The combination of MDC’s in vivo imaging and infrastructure, with WMIC’s heritage in radiochemistry, further strengthens the national PET Network, which has been established across the UK by MDC and leading academic centres of excellence. ” Find out more about MDCs PET Imaging expertise here.

Medicine 52

Medicine In-Vivo Packaging Packaging 52

pharmaphorum

SEPTEMBER 15, 2022

Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it to build on its foundational insights into precision in vivo engineering technology. The research was undertaken by world-renowned mRNA and cell therapy scientists and clinicians at the University of Pennsylvania.

In-Vivo 104

In-Vivo Engineer Scientist Life Science 104

Drug Discovery World

JULY 5, 2023

A fulfilling part of my job is meeting the scientists, companies, and institutions at the forefront of ground-breaking research that are advancing patient health outcomes. Mark Garner, PhD., RA: Please can you tell us a bit more about your role at Agilent? MG: I am responsible for Agilent’s cancer segment.

Research 98

Research Protein Scientist Immune Response 98

Drug Discovery World

JULY 3, 2023

This was centred around pre-clinical models (in vitro and in vivo) to support discovery and development, re-entering the fray with costimulatory agonists, and clinical development strategies for combinations with immune cell engagers​.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

pharmaphorum

APRIL 6, 2021

Shiva Kazerounian , Associate Director & Principal Scientist – In Vivo Pharmacology, Berg Health. There is a crucial need to progress candidates from bench to bedside. With that in mind, I am delighted to share the official agenda and speaker faculty for the 9th PREDiCT: Tumor Models Cell Therapy Summit.

In-Vivo 52

In-Vivo Clinical Design Scientist Medicine 52

Drug Discovery World

JANUARY 23, 2023

Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance. Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care.

FDA Approval 52

FDA Approval Drugs In-Vivo In-Vitro 52

Camargo

DECEMBER 22, 2021

For products that have an US RLD counterpart, FDA may waive in vivo study requirements, depending on the drug formulation, proposed indication, active ingredients, solubility, permeability, and other factors. However, they may generate undifferentiated labels that are not conducive to commercial success. Clinical Pharmacology.

Bioequivalency 169

Bioequivalency Production Genotoxicity In-Vivo 169

Drug Discovery World

NOVEMBER 16, 2022

In April 2021, life sciences solutions provider Molecular Devices launched its Organoid Innovation Centre (OIC), an initiative designed to help scientists leverage the potential of 3D biology throughout the drug discovery process. . 2D vs 3D . 2D biology has been used by pharmaceutical researchers for decades. 2D vs 3D .

Drugs 97

Drugs In-Vivo In-Vitro Scientist 97

Drug Discovery World

OCTOBER 3, 2022

As experimental data becomes bigger and more complex, scientists are challenged to make discoveries faster, consistently document and analyse their work, and easily collaborate across an organisation and with external partners. If an ELN is in the cloud, these benefits also come with no maintenance or upgrades required by the IT department.

Scientist 52

Scientist In-Vivo Drugs 52

Drug Discovery World

OCTOBER 27, 2023

With cues from a diverse population of tissue-specific cell types, extracellular matrix proteins, and biomechanical forces, cells grown in organ-chips closely emulate their in vivo counterparts and replicate tissue-level functions. But can organ-chips entirely replace other models? Not yet, according to Ewart.

Research 72

Research Gene Therapy In-Vivo In-Vitro 72

XTalks

NOVEMBER 3, 2023

The scientists on the advisory committee were particularly focused on the CRISPR gene editing technology itself and how companies like Vertex that are developing CRISPR-based therapies are ensuring their treatments are not making off-target gene edits. CRISPR works as genetic scissors to edit parts of the genome.

Gene Therapy 59

Gene Therapy Gene Gene Editing In-Vivo 59

Drug Discovery World

JULY 22, 2022

By Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences. Although immunotherapy has revolutionised cancer therapy, the effectiveness of currently available immunotherapies varies significantly across patients and treatment types. Jespersen et al.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

Drug Discovery World

OCTOBER 21, 2022

Not only is October Breast Cancer Awareness Month but October 21 is Wear it Pink 2022, Breast Cancer Now’s annual fundraising day. The last month has seen a number of leaps in our understanding of difficult to treat and treatment resistant breast cancers, so here are Drug Discovery World’s top 5 research breakthroughs.

In-Vivo 52

In-Vivo Research Drugs Engineer 52

pharmaphorum

APRIL 29, 2021

To achieve this, the agenda will allow delegates to: Explore the translation of BBB-penetrating antibodies to non-human primates , and new possibilities for in vivo brain imaging of antibody neuropharamacokinetics. A Meeting Point for the Field’s Experts. 3-day Conference | June 28-30, 2021. About Hanson Wade.

Drug Delivery 52

Drug Delivery Gene Therapy In-Vivo Antibody 52

Camargo

FEBRUARY 10, 2021

Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high. Approaches to Pharmacokinetic Analysis.

Production 133

Production Bioavailability In-Vivo Bioequivalency 133

Drug Discovery World

JUNE 30, 2023

This pairing includes reprogrammed cells for both wild and mutation-specific Huntington’s Disease (H), Amyotrophic Lateral Sclerosis (ALS), and Alzheimer’s Disease (AD) and is expanding to include custom disease-relevant mutations. Disease relevant in vitro assays improve translation in vivo, leading to clinical success.

Development 52

Development Drugs In-Vitro Gene Therapy 52

Drug Discovery World

JUNE 7, 2023

LC : As we describe in Nature Reviews Cancer (NRC), scientists have known since the 1970s that tumours were populated by immune cells; however, it took several years of pre-clinical studies to prove that macrophages were key players in tumour progression. DS: Congratulations on the publication of your discoveries in Nature Reviews Cancer.

In-Vivo 52

In-Vivo Gene Editing Engineer Bioinformatics 52

Delveinsight

FEBRUARY 11, 2021

The scientists analyzed samples from patients with the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC). The scientists analyzed samples from patients with the most common pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC). Enhancing the response to immuno-oncology in pancreatic cancer.

Gene Therapy 52

Gene Therapy Gene Immune Response In-Vivo 52

Delveinsight

FEBRUARY 25, 2021

Electroporation is used for ex vivo delivery of therapies to blood and immune cells. The company’s in vivo therapies reach the eye and central nervous system via adeno-associated viruses, while its liver therapies employ lipid nanoparticles (LNPs). Beam employs three approaches to deliver its genetic medicines to cells.

DNA 52

DNA In-Vivo Genetics Medicine 52

The Pharma Data

NOVEMBER 24, 2020

Fidelta, located in R&D facilities in Croatia, currently has 181 employees, including more than 150 scientists. Selvita expects the acquisition will help the company “build a competitive advantage” in key business areas, including DMPK, in vivo pharmacology as well as toxicology. million, or over $37 million in U.S.

Drugs 52

Drugs In-Vivo Marketing Development 52

FDA Law Blog

FEBRUARY 2, 2023

The law defines this term to mean “a test conducted in vitro, in silico, or in chemico, or a nonhuman in vivo test that occurs before or during the clinical trial phase of the investigation of the safety and effectiveness of a drug.” Tobolowsky & Charles G. FDORA § 3209(a)(1). FDORA § 3209(a)(2). 42 U.S.C. § 262(k)(2)(A)(i)(I).

Clinical Trials 64

Clinical Trials Clinical Trials In-Vivo In-Vitro 64

Drug Discovery World

AUGUST 3, 2022

Currently, only a small number of CPP-based oligonucleotide delivery examples have been reported for in vivo application. In a recent publication from scientists at the University of Bordeaux, a CPP-based nanoparticles approach was reportedly used to deliver siRNA into cancer cells of solid tumours. Covalent (thiol-maleimide) 7.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

Drug Discovery World

FEBRUARY 2, 2024

If I hadn’t had that,” he says, “I would certainly not be working at Tetra, today.” AI in drug discovery Answering the question of where technology is being implemented to progress the drug discovery process, Tarselli says: “You know that what everyone wants to say right now is AI (artificial intelligence).

In-Vivo 52

In-Vivo Compliance Drugs Pharma Companies 52

XTalks

OCTOBER 1, 2020

Leaving academia for industry is a route that academic scientists and professors did not traditionally pursue in the past due to perceived differences in skillsets, experiences and even associated stigmas. WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation.

Scientist 52

Scientist In-Vitro Research Life Science 52